PHARMACOTHERAPEUTICS FOR ADVANCED PRACTICE f# f# f#
NURSE PRESCRIBERS 5TH EDITION WOO ROBINSON TEST
f# f# f# f# f# f# f#
BANK
f#
CHAPTERf#1.f#THEf#ROLEf#OF
THEf#NURSE
f#
f# PractitionerMultiple f#Choice
Identify f#the f#choice f#that f#best f#completes f#the f#statement f#or f#answers f#the f#question.
f# 1. f#Nurse f#practitioner f#prescriptive f#authorityf#is f#regulated f# by:
1. Thef#National f#Council f#off#State f#Boardsf#of f#Nursing
2. Thef#U.S. f#Drug f#Enforcement f#Administration
3. Thef#State f#Board f#of f#Nursing f#for f#each f#state
4. The f#State f#Board f#of f#Pharmacy
f# 2.f#The f#benefits f#to f#the f#patient f#of f#having f#an f#Advanced f#Practicef#Registered f#Nurse
f#(APRN) f#prescriberinclude:
1. Nursesf#know f#more f#about f#Pharmacology f#thanf#otherf#prescribers f#because f#they
f#take f#it both f# in f#their f#basic f#nursing f#program f#and f#in f#their f#APRN
.Y
f#program.
2. Nurses f#caref#for f#the f#patient f#from f#af#holistic f#approach f#and f#include f#the
f#patient f#in d ecision f# making f#regarding f#their f#care.
.Y
3. APRNsf#are f#less f#likely f#toprescribe f#narcotics f#and f#other f#controlled f#substances.
4. APRNsf#aref#able f#to f#prescribef#independentlyf#in f#all f#states, f#whereas f#a
physician’sassistant f#needs f#to f#have f#a f#physician f#supervising f#their f#practice.
.Y
f# 3. f#Clinical f#judgment f#in f#prescribing f # includes:
1. Factoring f#inf#the f#cost f#to f#thef#patient f#off#the f#medication f#prescribed
2. Always f#prescribingf#the f#newest f#medication f#available f#forf#thef#disease f#process
3. Handing f#out f#drug f#samples f#to f#poor f#patients
4. Prescribingf#all f#generic f#medications f#to f#cut f#costs
f# 4. f#Criteria f#for f#choosing f#an f#effective f#drug f#for f#a f#disorder f # include:
1. Asking f#the f#patient f#what f#drug f#they f#think f#would f#work f#best f#forf#them
2. Consultingf#nationallyf#recognized f#guidelines f#forf#disease f#management
3. Prescribing f#medications f#that f#are f#available f#as f#samples f#before f#writing f#a f#prescription
4. Following f#U.S. f#Drug f#Enforcement f#Administration f#guidelinesf#for f#prescribing
f# 5. f#Nurse f#practitioner f#practice f#may f#thrive f#under f#health-care f#reform f#because f # of:
1. Thef#demonstrated f#abilityf#of f#nursef#practitioners f#tof#control f#costs f#and
f#improve f#patiento utcomes
.Y
2. Thef#fact f#that f#nurse f#practitioners f#will f#be f#able f#tof#practice f#independently
3. The f#fact f#that f#nurse f#practitioners f#will f#have f#full f#reimbursement f#under
f#health- f#carereform
4. Thef#ability f#to f#shift f#accountability f#for f#Medicaid f#to f#the f#state f#level
,
,Chapterf#1. f#Thef#Rolef#of f#the
f#Nurse f#PractitionerAnswer
f#Section
MULTIPLE f#CHOICE
1. f#ANS: f # 3 PTS: 1
2. f#ANS: f # 2 PTS: 1
3. f#ANS: f # 1 PTS: 1
4. f#ANS: f # 2 PTS: 1
5. f#ANS: f # 1 PTS: 1
Chapter f#2. f#Reviewf#off#Basic f#Principles f#of
PharmacologyMultiple f#Choice
f#
Identify f#the f#choice f#that f#best f#completes f#the f#statement f#or f#answers f#the f#question.
f# 1. f#Af#patient’s f#nutritional f#intakef#and f#laboratory f#results f#reflect f#hypoalbuminemia. f#This f#is
f#critical f#toprescribingbecause:
1. Distribution f#off#drugs f#tof#target f#tissuef#may f#be f#affected.
2. Thef#solubility f#of f#the f#drug will f#not f#match f#the f#site f#of f#absorption.
.Y
3. Theref#will f#be f#less f#free f#drug f#available f#to f#generate f#an f#effect.
4. Drugs f#bound f#to f#albumin f#are f#readily f#excreted f#by f#the f#kidneys.
f# 2. f#Drugs f#that f#have f#a f#significant f#first-pass f # effect:
1. Must f#be f#given f#by f#the f#enteral f#(oral) f#route f#only
2. Bypass f#the f#hepatic f#circulation
3. Are f#rapidly f#metabolized f#by f#the f#liver f#and f#mayf#have f#little f#if f#anyf#desired f#action
4. Are f#converted f#by f#the f#liver f#to f#more f#active f#and f#fat-soluble f#forms
f# 3. f#The f#route f#of f#excretion f#of f#a f#volatile f#drug f#will f#likely f#be f# the:
1. Kidneys
2. Lungs
3. Bile f#and f#feces
4. Skin
f# 4. f#Medroxyprogesteronef#(Depo f#Provera) f#is f#prescribedf#intramuscularlyf#(IM) f#to
f#create f#a f#storagereservoir f#of f#the f#drug. f#Storage f#reservoirs:
1. Assuref#that f#the f#drug f#will f#reach f#itsf#intended f#target f#tissue
2. Are f#the f#reason f#for f#giving f#loading f#doses
3. Increase f#thef#length f#of f#time f#a f#drugf#is f#available f#and f#active
4. Are f#most f#common f#in f#collagen f#tissues
f# 5. f#The f#NP f#chooses f#to f#give f#cephalexin f#every f#8 f#hours f#based f#on f#knowledge f#of f#the f#drug’s:
1. Propensity#fto f#go f#to f#thef#target f#receptor
2. Biological f#half-life
3. Pharmacodynamics
4. Safety f#and f#side f#effects
, f# 6. f#Azithromycin f#dosing f#requires f#that f#the f#first f#day’s f#dosage f#bef#twice f#those f#of f#the f#other f#4
f#days f#of f#theprescription. f#This f#is f#considered f#a f#loading f#dose. f#A f#loading f#dose:
1. Rapidly f#achieves f#drug f#levels f#inf#the f#therapeutic f#range
2. Requires f#four- f#to f#five-half-lives f#to f#attain
3. Is f#influenced f#byf#renal f#function
4. Is f#directly f#related f#to f#the f#drug f#circulating f#to f#the f#target f#tissues
f# 7. f#The f#point f#inf#time f#onf#the f#drug f#concentration f#curve f#that f#indicates f#the f#first f#sign f#of f#af#therapeutic
f#effect is f# the:
.Y
1. Minimum f#adverse f#effect f#level
2. Peak f#of f#action
NURSE PRESCRIBERS 5TH EDITION WOO ROBINSON TEST
f# f# f# f# f# f# f#
BANK
f#
CHAPTERf#1.f#THEf#ROLEf#OF
THEf#NURSE
f#
f# PractitionerMultiple f#Choice
Identify f#the f#choice f#that f#best f#completes f#the f#statement f#or f#answers f#the f#question.
f# 1. f#Nurse f#practitioner f#prescriptive f#authorityf#is f#regulated f# by:
1. Thef#National f#Council f#off#State f#Boardsf#of f#Nursing
2. Thef#U.S. f#Drug f#Enforcement f#Administration
3. Thef#State f#Board f#of f#Nursing f#for f#each f#state
4. The f#State f#Board f#of f#Pharmacy
f# 2.f#The f#benefits f#to f#the f#patient f#of f#having f#an f#Advanced f#Practicef#Registered f#Nurse
f#(APRN) f#prescriberinclude:
1. Nursesf#know f#more f#about f#Pharmacology f#thanf#otherf#prescribers f#because f#they
f#take f#it both f# in f#their f#basic f#nursing f#program f#and f#in f#their f#APRN
.Y
f#program.
2. Nurses f#caref#for f#the f#patient f#from f#af#holistic f#approach f#and f#include f#the
f#patient f#in d ecision f# making f#regarding f#their f#care.
.Y
3. APRNsf#are f#less f#likely f#toprescribe f#narcotics f#and f#other f#controlled f#substances.
4. APRNsf#aref#able f#to f#prescribef#independentlyf#in f#all f#states, f#whereas f#a
physician’sassistant f#needs f#to f#have f#a f#physician f#supervising f#their f#practice.
.Y
f# 3. f#Clinical f#judgment f#in f#prescribing f # includes:
1. Factoring f#inf#the f#cost f#to f#thef#patient f#off#the f#medication f#prescribed
2. Always f#prescribingf#the f#newest f#medication f#available f#forf#thef#disease f#process
3. Handing f#out f#drug f#samples f#to f#poor f#patients
4. Prescribingf#all f#generic f#medications f#to f#cut f#costs
f# 4. f#Criteria f#for f#choosing f#an f#effective f#drug f#for f#a f#disorder f # include:
1. Asking f#the f#patient f#what f#drug f#they f#think f#would f#work f#best f#forf#them
2. Consultingf#nationallyf#recognized f#guidelines f#forf#disease f#management
3. Prescribing f#medications f#that f#are f#available f#as f#samples f#before f#writing f#a f#prescription
4. Following f#U.S. f#Drug f#Enforcement f#Administration f#guidelinesf#for f#prescribing
f# 5. f#Nurse f#practitioner f#practice f#may f#thrive f#under f#health-care f#reform f#because f # of:
1. Thef#demonstrated f#abilityf#of f#nursef#practitioners f#tof#control f#costs f#and
f#improve f#patiento utcomes
.Y
2. Thef#fact f#that f#nurse f#practitioners f#will f#be f#able f#tof#practice f#independently
3. The f#fact f#that f#nurse f#practitioners f#will f#have f#full f#reimbursement f#under
f#health- f#carereform
4. Thef#ability f#to f#shift f#accountability f#for f#Medicaid f#to f#the f#state f#level
,
,Chapterf#1. f#Thef#Rolef#of f#the
f#Nurse f#PractitionerAnswer
f#Section
MULTIPLE f#CHOICE
1. f#ANS: f # 3 PTS: 1
2. f#ANS: f # 2 PTS: 1
3. f#ANS: f # 1 PTS: 1
4. f#ANS: f # 2 PTS: 1
5. f#ANS: f # 1 PTS: 1
Chapter f#2. f#Reviewf#off#Basic f#Principles f#of
PharmacologyMultiple f#Choice
f#
Identify f#the f#choice f#that f#best f#completes f#the f#statement f#or f#answers f#the f#question.
f# 1. f#Af#patient’s f#nutritional f#intakef#and f#laboratory f#results f#reflect f#hypoalbuminemia. f#This f#is
f#critical f#toprescribingbecause:
1. Distribution f#off#drugs f#tof#target f#tissuef#may f#be f#affected.
2. Thef#solubility f#of f#the f#drug will f#not f#match f#the f#site f#of f#absorption.
.Y
3. Theref#will f#be f#less f#free f#drug f#available f#to f#generate f#an f#effect.
4. Drugs f#bound f#to f#albumin f#are f#readily f#excreted f#by f#the f#kidneys.
f# 2. f#Drugs f#that f#have f#a f#significant f#first-pass f # effect:
1. Must f#be f#given f#by f#the f#enteral f#(oral) f#route f#only
2. Bypass f#the f#hepatic f#circulation
3. Are f#rapidly f#metabolized f#by f#the f#liver f#and f#mayf#have f#little f#if f#anyf#desired f#action
4. Are f#converted f#by f#the f#liver f#to f#more f#active f#and f#fat-soluble f#forms
f# 3. f#The f#route f#of f#excretion f#of f#a f#volatile f#drug f#will f#likely f#be f# the:
1. Kidneys
2. Lungs
3. Bile f#and f#feces
4. Skin
f# 4. f#Medroxyprogesteronef#(Depo f#Provera) f#is f#prescribedf#intramuscularlyf#(IM) f#to
f#create f#a f#storagereservoir f#of f#the f#drug. f#Storage f#reservoirs:
1. Assuref#that f#the f#drug f#will f#reach f#itsf#intended f#target f#tissue
2. Are f#the f#reason f#for f#giving f#loading f#doses
3. Increase f#thef#length f#of f#time f#a f#drugf#is f#available f#and f#active
4. Are f#most f#common f#in f#collagen f#tissues
f# 5. f#The f#NP f#chooses f#to f#give f#cephalexin f#every f#8 f#hours f#based f#on f#knowledge f#of f#the f#drug’s:
1. Propensity#fto f#go f#to f#thef#target f#receptor
2. Biological f#half-life
3. Pharmacodynamics
4. Safety f#and f#side f#effects
, f# 6. f#Azithromycin f#dosing f#requires f#that f#the f#first f#day’s f#dosage f#bef#twice f#those f#of f#the f#other f#4
f#days f#of f#theprescription. f#This f#is f#considered f#a f#loading f#dose. f#A f#loading f#dose:
1. Rapidly f#achieves f#drug f#levels f#inf#the f#therapeutic f#range
2. Requires f#four- f#to f#five-half-lives f#to f#attain
3. Is f#influenced f#byf#renal f#function
4. Is f#directly f#related f#to f#the f#drug f#circulating f#to f#the f#target f#tissues
f# 7. f#The f#point f#inf#time f#onf#the f#drug f#concentration f#curve f#that f#indicates f#the f#first f#sign f#of f#af#therapeutic
f#effect is f# the:
.Y
1. Minimum f#adverse f#effect f#level
2. Peak f#of f#action
